Adjuvant Sunitinib for High-risk Renal Cell Carcinoma After Nephrectomy: Subgroup Analyses and Updated Overall Survival Results

J. Motzer, Robert; Ravaud, Alain; Patard, Jean‐Jacques; Pandha, Hardev; J. George, Daniel; Patel, Anup; Chang, Yen-Hwa; Escudier, Bernard; Donskov, Frede; Magheli, Ahmed; Cartenì, Giacomo; Laguerre, Brigitte; Tomczak, Piotr; Breza, J.; Gerletti, Paola; Lechuga, Mariajosé; Lin, Xun; Casey, Michelle; Serfass, Lucile; J. Pantuck, Allan; Staehler, Michael

doi:10.1016/j.eururo.2017.09.008

Public

Adjuvant Sunitinib for High-risk Renal Cell Carcinoma After Nephrectomy: Subgroup Analyses and Updated Overall Survival Results

Published in European Urology • Sep 28, 2017

Authors:

Robert J. Motzer

Alain Ravaud

Jean‐Jacques Patard

Abstract

BACKGROUND: Adjuvant sunitinib significantly improved disease-free survival (DFS) versus placebo in patients with locoregional renal cell carcinoma (RCC) at high risk of recurrence after nephrectomy (hazard ratio [HR] 0.76, 95% confidence interval [CI] 0.59-0.98; p=0.03). OBJECTIVE: To report the re...

Subject

Medicine

Hazard ratio

Sunitinib

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!